224 related articles for article (PubMed ID: 32259776)
1. Pharmacogenetics of antiemetics for chemotherapy-induced nausea and vomiting: A systematic review and meta-analysis.
Eliasen A; Dalhoff K; Mathiasen R; Schmiegelow K; Rechnitzer C; Schelde AB; Perwitasari DA; Tsuji D; Brok J
Crit Rev Oncol Hematol; 2020 May; 149():102939. PubMed ID: 32259776
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenetics of chemotherapy-induced nausea and vomiting.
Sugino S; Janicki PK
Pharmacogenomics; 2015 Jan; 16(2):149-60. PubMed ID: 25616101
[TBL] [Abstract][Full Text] [Related]
3. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
4. Effect of the allelic variants of ABCB1, CYP2D6 and HTR3B on response of ramosetron to prevent chemotherapy-induced nausea and vomiting in Korean cancer patients.
Kang G; Kim KR; Shim HJ; Hwang JE; Bae WK; Chung IJ; Kim HN; Lee J; Choi K; Shin HY; Kim JK; Jeong SW; Cho SH
Asia Pac J Clin Oncol; 2017 Feb; 13(1):53-60. PubMed ID: 27488933
[TBL] [Abstract][Full Text] [Related]
5. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
6. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
7. Latest Update on Prevention of Acute Chemotherapy-Induced Nausea and Vomiting in Pediatric Cancer Patients.
Sherani F; Boston C; Mba N
Curr Oncol Rep; 2019 Aug; 21(10):89. PubMed ID: 31418119
[TBL] [Abstract][Full Text] [Related]
8. Association of ABCB1, 5-HT3B receptor and CYP2D6 genetic polymorphisms with ondansetron and metoclopramide antiemetic response in Indonesian cancer patients treated with highly emetogenic chemotherapy.
Perwitasari DA; Wessels JA; van der Straaten RJ; Baak-Pablo RF; Mustofa M; Hakimi M; Nortier JW; Gelderblom H; Guchelaar HJ
Jpn J Clin Oncol; 2011 Oct; 41(10):1168-76. PubMed ID: 21840870
[TBL] [Abstract][Full Text] [Related]
9. Neurokinin-1 receptor antagonists for chemotherapy-induced nausea and vomiting: a systematic review.
dos Santos LV; Souza FH; Brunetto AT; Sasse AD; da Silveira Nogueira Lima JP
J Natl Cancer Inst; 2012 Sep; 104(17):1280-92. PubMed ID: 22911671
[TBL] [Abstract][Full Text] [Related]
10. Genetic Influence on Chemotherapy-Induced Nausea and Vomiting: A Narrative Review.
Kiernan J
Oncol Nurs Forum; 2016 May; 43(3):389-93. PubMed ID: 27105200
[TBL] [Abstract][Full Text] [Related]
11. Reviewing current and emerging antiemetics for chemotherapy-induced nausea and vomiting prophylaxis.
Natale JJ
Hosp Pract (1995); 2015; 43(4):226-34. PubMed ID: 26308912
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
13. A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.
Singh KP; Dhruva AA; Flowers E; Kober KM; Miaskowski C
Crit Rev Oncol Hematol; 2018 Jan; 121():51-61. PubMed ID: 29279099
[TBL] [Abstract][Full Text] [Related]
14. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta-analysis of randomised controlled trials.
Zhou JG; Huang L; Jin SH; Xu C; Frey B; Ma H; Gaipl US
ESMO Open; 2020 Feb; 5(1):. PubMed ID: 32079622
[TBL] [Abstract][Full Text] [Related]
16. [Experience with the use of palonosetron (onicit) in patients with solid tumors receiving cytostatic therapy].
Vladimirova LY; Mitashok IS; Storozhakova AE; Kalabanova EA; Svetitskaya YV; Kabanov SN
Vopr Onkol; 2015; 61(4):653-5. PubMed ID: 26571839
[TBL] [Abstract][Full Text] [Related]
17. Anti-emetic drugs in oncology: pharmacology and individualization by pharmacogenetics.
Perwitasari DA; Gelderblom H; Atthobari J; Mustofa M; Dwiprahasto I; Nortier JW; Guchelaar HJ
Int J Clin Pharm; 2011 Feb; 33(1):33-43. PubMed ID: 21365391
[TBL] [Abstract][Full Text] [Related]
18. Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?
Trammel M; Roederer M; Patel J; McLeod H
Curr Oncol Rep; 2013 Jun; 15(3):276-85. PubMed ID: 23512709
[TBL] [Abstract][Full Text] [Related]
19. Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting.
Navari RM; Aapro M
N Engl J Med; 2016 Apr; 374(14):1356-67. PubMed ID: 27050207
[No Abstract] [Full Text] [Related]
20. Pathogenesis-based treatment of chemotherapy-induced nausea and vomiting--two new agents.
Navari RM
J Support Oncol; 2003; 1(2):89-103. PubMed ID: 15352652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
